Diovan valsartan: Phase III data

Novartis reported data from the prospective, double-blind, placebo-controlled, international Phase III NAVIGATOR trial in 9,306 patients with impaired glucose tolerance and cardiovascular disease or risk factors receiving either once-daily Diovan or thrice-daily Starlix nateglinide. Diovan met the co-primary endpoint of significantly reducing the cumulative incidence of diabetes vs. placebo (33.1% vs. 36.8%, p<0.001), but missed the co-primary endpoints of significantly reducing the incidence of core (8.1% vs. 8.1%, p=0.42) and extended cardiovascular outcomes (14.5% vs. 14.8%, p=0.22) vs. placebo. ...